Metabolic HealthTirzepatide Users Had Fewer Anemia Diagnoses Than GLP-1 Drug Users in a Large Cohort
Weight-loss drugs can change how much people eat, which raises a fair question: do they raise the risk of nutrient-related anemia? Researchers used a large U.S.-based electronic health records network to compare adults with type 2 diabetes and overweight or obesity who started tirzepatide with those who started a GLP-1 receptor agonist such as semaglutide or liraglutide. After matching, each group had 67,608 people. Over one year, 2.13% of tirzepatide users and 2.84% of GLP-1 users were diagnosed with nutritional deficiency anemia, a modestly lower hazard with tirzepatide (HR 0.88). The difference was driven by iron deficiency anemia. Vitamin B12 and folate results were inconclusive. This is an observational association, not proof that tirzepatide protects against anemia, and the authors note residual confounding and differences in follow-up and diagnosis. Notably, neither drug class showed a clear signal of harm here.